|
WO2020136232A1
|
|
Immunosuppressive m2 protein
|
|
WO2020136235A1
|
|
M2-defective poxvirus
|
|
US2019070285A1
|
|
Composition for treating HBV infection
|
|
WO2019020543A1
|
|
Oncolytic viruses expressing agents targeting metabolic immune modulators
|
|
KR20200026894A
|
|
Personalized vaccines
|
|
EP3562946A1
|
|
Oncolytic viruses and therapeutic molecules
|
|
WO2018091680A1
|
|
Cowpox-based oncolytic vectors
|
|
US2019328869A1
|
|
Immunotherapeutic product and mdsc modulator combination therapy
|
|
EP3452081A1
|
|
Combination therapy with cpg tlr9 ligand
|
|
WO2016131945A1
|
|
Combination product with autophagy modulator
|
|
CA2975432A1
|
|
Immunotherapeutic vaccine and antibody combination therapy
|
|
MX2017007178A
|
|
Stable liquid vaccinia virus formulations.
|
|
WO2016020538A1
|
|
Hbv vaccine and antibody combination therapy to treat hbv infections
|
|
KR20170033364A
|
|
Combination of oncolytic virus with immune checkpoint modulators
|
|
EP3169341A1
|
|
Oncolytic virus for expression of immune checkpoint modulators
|
|
AU2015243297A2
|
|
Poxviral oncolytic vectors
|
|
RU2695462C2
|
|
Hybridisation of heterooligomer mycobacterial antigens
|
|
US2015017126A1
|
|
Poxviral oncolytic vectors
|
|
TW201436802A
|
|
Modulation of monocytes, or precursors thereof, differentiation
|
|
TW201417820A
|
|
Virus-containing formulation and use thereof
|
